ArticleJournal of inflammation research2025
Investigating the Underlying Mechanisms of Ma-Xing-Shi-Gan-Tang on Asthma via Metabolomics and Network Pharmacology.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From gut microbiota dysbiosis to immune dysregulation: pathogenic mechanisms and emerging therapeutic perspectives in pediatric asthma.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Ma-xing-shi-gan-tan (MXSGT) was first published in "Shang-han-lun". It functions as a heat-clearing agent, lung-clearing formula, and asthma reliever. This study aims to evaluate the therapeutic effect of MXSGT on asthma and elucidate its underlying mechanisms. Methods: Key components of MXSGT were identified using ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS). A rat model of asthma induced by ovalbumin (OVA) was employed to assess MXSGT efficacy. The fundamental mechanisms of MXSGT in asthma treatment were investigated through metabolomic analysis, network pharmacology, and molecular docking. Results: MXSGT treatment demonstrated significant protective effects in OVA-induced asthmatic rats, evidenced by its suppression of inflammatory mediators including nuclear factor kappa B complex p65 (NF-κBp65), p38 mitogen-activated protein kinase (p38-MAPK), and transforming growth factor-β1 (TGF-β1). Metabolomic analysis revealed 9 MXSGT blood components and 12 differential metabolites associated with MXSGT treatment. Further analysis indicated that MXSGT's therapeutic benefit in asthma involves modulation of metabolic pathways such as the citric acid cycle (TCA cycle), alanine and aspartate metabolism, tyrosine metabolism, among others. Succinic acid was identified as the metabolite most prominently involved in these pathways. Additionally, network pharmacology identified TNF as a key target linking blood components and differential metabolites, mediating anti-asthma effects through MAPK and NF-κB signaling pathways. Conclusion: Our findings demonstrate that MXSGT exerts anti-inflammatory effects in asthma treatment by inhibiting MAPK and NF-κB signaling pathways and regulating host metabolites and metabolic pathways. These insights provide novel perspectives on MXSGT's role in asthma management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.